Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to establish the clinical disease outcomes and features of CDAD associated with variant tcdC genotypes. Two hypotheses are to be tested in this study:

1. Severe CDAD and tcdC truncation:

Severe CDAD (defined by death and/or colectomy or secondary endpoints) is associated with severe truncations (> 6 amino acid residues) in TcdC, a negative regulator of toxin A/B production.

2. Disease in low risk populations (patients never exposed to health care facilities and/or patients who never received antibiotics) of any severity is attributable to strains of C. difficile with severe tcdC truncation.


Clinical Trial Description

The following information will be collected: age, sex, occupation, hospital location at the time of positive culture (ER, medical ward, ICU etc), prior hospitalization, receipt of outpatient dialysis, home care or other regular medical care (eg, outpatient chemotherapy), date of specimen collection, presence of invasive devices, receipt of antibiotics, including their type and whether they were adequate for the resistance profile of the organism, prior positive microbiologic cultures, time and location of positive cultures, underlying diseases and severity of illness, presence of urinary or intravascular devices, recent immunomodulative therapies or radiation therapy, physical exam findings, laboratory and radiographical data, antimicrobial usage within 6 months of onset of the infection, microbiological data and resistance patterns, choice of antibiotics once organism identified, bacteriological outcomes, laboratory results, demographic information, medications, clinical outcome,gender, height, weight, ethnicity, past medical history and outcomes. We will collect information retrospectively. ;


Study Design

Observational Model: Case Control, Time Perspective: Retrospective


Related Conditions & MeSH terms


NCT number NCT00446355
Study type Observational
Source University of Pittsburgh
Contact
Status Completed
Phase N/A
Start date February 2007
Completion date April 2009

See also
  Status Clinical Trial Phase
Recruiting NCT04179201 - Study on Clostridium Difficile Infection in Chinese Patients With Inflammatory Bowel Disease
Completed NCT02563106 - A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI Phase 2
Completed NCT00214461 - Safety, Tolerability, and Immunogenicity of a Clostridium Difficile Toxoid Vaccine in Healthy Elderly Volunteers Phase 1
Completed NCT00314951 - Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) Phase 3
Completed NCT00328263 - Efficacy and Safety of BIO-K + CL1285 in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Patients Phase 3
Completed NCT00127803 - Safety, Tolerability, and Immunogenicity Study of a Clostridium Difficile Toxoid Vaccine in Healthy Adult Volunteers Phase 1
Completed NCT00350298 - Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease Phase 2
Withdrawn NCT05077085 - Bezlotoxumab Versus FMT for Multiple Recurrent CDI Phase 4
Recruiting NCT02681068 - MicroTrans - A Multicenter Registry of Fecal Microbiota Transplantation N/A
Not yet recruiting NCT06277999 - C.Difficile Observational Study
Terminated NCT00384527 - Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease Phase 3
Completed NCT00269399 - A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) Phase 3
Completed NCT04026009 - Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years Phase 1
Completed NCT00468728 - PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) Phase 3